Ruben van Eijk
@rpavaneijk.bsky.social
ALS/MND Researcher @ UMCU | Clinical Trial Methodology, Outcomes & Statistics | Part-time cyclist 🚴♂️
Reposted by Ruben van Eijk
@rpavaneijk.bsky.social & colleagues conducted a multi-year prospective cohort study of 97 patients with #ALS. Their findings: an #accelerometer -based measure is predictive of disease progression and related to patient-reported functioning: www.thelancet.com/journals/ebi...
Remote monitoring of amyotrophic lateral sclerosis using wearable sensors detects differences in disease progression and survival: a prospective cohort study
The results serve as motivation to incorporate accelerometer-derived outcomes in clinical
trials, which is essential for further validation of these markers to meaningful endpoints.
www.thelancet.com
March 5, 2025 at 6:15 PM
@rpavaneijk.bsky.social & colleagues conducted a multi-year prospective cohort study of 97 patients with #ALS. Their findings: an #accelerometer -based measure is predictive of disease progression and related to patient-reported functioning: www.thelancet.com/journals/ebi...
Reposted by Ruben van Eijk
Our study on the safety and tolerability of Trimetazidine in #ALS @braincomms.bsky.social
Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study
@rpavaneijk.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social
academic.oup.com/braincomms/a...
Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study
@rpavaneijk.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social
academic.oup.com/braincomms/a...
February 10, 2025 at 10:10 AM
Our study on the safety and tolerability of Trimetazidine in #ALS @braincomms.bsky.social
Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study
@rpavaneijk.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social
academic.oup.com/braincomms/a...
Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study
@rpavaneijk.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social
academic.oup.com/braincomms/a...
Dropout & attrition in #ALS #MND trials is a major challenge. We have created an #open-access calculator to estimate attrition rates for a given study duration, which can used to guide trial design and sample size calculations (tricals.shinyapps.io/Attrition/); the accompanying paper: rdcu.be/d3n36
December 13, 2024 at 10:15 AM
Dropout & attrition in #ALS #MND trials is a major challenge. We have created an #open-access calculator to estimate attrition rates for a given study duration, which can used to guide trial design and sample size calculations (tricals.shinyapps.io/Attrition/); the accompanying paper: rdcu.be/d3n36
New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...
Rethinking phase 2 trials in amyotrophic lateral sclerosis
There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria
academic.oup.com
December 10, 2024 at 3:14 PM
New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...